NCT03435406

Brief Summary

to investigate the prevalence of hepatopulmonary syndrome in cirrhosis patients caused by Hepatitis B in western China

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2017

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 27, 2017

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

February 2, 2018

Completed
17 days until next milestone

First Posted

Study publicly available on registry

February 19, 2018

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2018

Completed
Last Updated

February 19, 2018

Status Verified

February 1, 2018

Enrollment Period

8 months

First QC Date

February 2, 2018

Last Update Submit

February 9, 2018

Conditions

Keywords

Hepatitis B, ChronicCirrhosisHepatopulmonary Syndrome

Outcome Measures

Primary Outcomes (7)

  • transthoracic contrast enhanced echocardiography (CEE)

    through the ultrasound to evaluate the imagine of cardiac cavity after intravenous injection of agitated saline

    During the operation

  • arterial blood gas

    arterial blood gas analysis was performed through the radial artery.

    During the operation

  • medical history

    The medical history was collected through consultation.

    During the operation

  • acropachy

    acropachy was examined by inspection

    During the operation

  • spider angioma

    spider angioma was examined by inspection

    During the operation

  • liver palms

    liver palms was examined by inspection

    During the operation

  • oxygen saturation

    oxygen saturation was examined by pulse oximetry

    During the operation

Secondary Outcomes (2)

  • the content of bone morphogenetic protein (BMP9) in the patients with and without HPS

    4 to 6 months after the study completion

  • micro ribonucleic acid 144 (miR144), micro ribonucleic acid 200 (miR200) in the patients with and without HPS

    4 to 6 months after the study completion

Study Arms (2)

cirrhosis with HPS

Diagnosed as HPS

cirrhosis without HPS

Not Diagnosed as HPS

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients were selected with cirrhosis caused by HBV including Southwest Hospital, the first affiliated hospital of Chongqing Medical University, the People's hospital of Rongchang district and Qijiang District people's hospital

You may qualify if:

  • Age: 18-80 years old;
  • American association of anesthesiologists(ASA) score: I-III;
  • Ability to comply with research programmes;
  • Voluntary participation in the study;
  • Has the history of HBV infection;
  • No primary cardiopulmonary disease (heart disease, emphysema, pneumonia, asthma, etc.)

You may not qualify if:

  • Severe heart, lung, kidney disease coexisted;
  • American association of anesthesiologists(ASA) score≥IV; forced expiratory volume at one second (FEV1) or forced vital capacity (FVC) \<70%, or FEV1 / FVC \<0.70;
  • Mental state could not cooperate
  • Absence of written informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Anesthesiology, Southwest Hospital Third Military Medical University

Chongqing, Chongqing Municipality, 400038, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

serum

MeSH Terms

Conditions

Hepatopulmonary SyndromeHepatitis B, ChronicFibrosis

Condition Hierarchy (Ancestors)

Liver DiseasesDigestive System DiseasesLung DiseasesRespiratory Tract DiseasesHepatitis BBlood-Borne InfectionsCommunicable DiseasesInfectionsHepadnaviridae InfectionsDNA Virus InfectionsVirus DiseasesHepatitis, Viral, HumanHepatitis, ChronicHepatitisChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Lu K Zhi, PhD

    Department of Anesthesiology, Southwest Hospital Third Military Medical University

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Institute of Anesthesiology, Southwest Hospital, Third Military Medical University Affiliation: Southwest Hospital, China

Study Record Dates

First Submitted

February 2, 2018

First Posted

February 19, 2018

Study Start

July 27, 2017

Primary Completion

April 1, 2018

Study Completion

April 1, 2018

Last Updated

February 19, 2018

Record last verified: 2018-02

Locations